Name

ReproCELL

Legal name

REPROCELL Inc.

Website

https://reprocell.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Stem Cell Research and Regenerative Medicine Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Stem cell services
• Regenerative medicine
• IPSC reprogramming
• Gene editing services
• GMP cell manufacturing

Headquarters

HQ city

Beltsville

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales: Sale of biological products including reagents, cells, culture media, and labware for stem cell research and cell therapy development
2. Clinical Stem Cell Services: GMP-compliant manufacturing and processing services for clinical-grade stem cell products for therapeutic applications
3. Research Stem Cell Services: Research-grade stem cell products and services including iPSC generation, characterization, and differentiation
4. Preclinical and Drug Discovery Services: Contract research services for preclinical studies and drug discovery using stem cell platforms
5. Clinical Laboratory Services: Diagnostic laboratory services including genomic analysis and tissue sample processing
6. Genomic Services: Genomic analysis and sequencing services for research and clinical applications

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

ReproCELL provides clinical and preclinical research services and products in stem cell technology, regenerative medicine, and drug discovery. The company offers proprietary iPSC reprogramming (StemRNA™), AI-designed CRISPR gene editing (StemEdit), GMP-compliant Master Cell Bank manufacturing, regenerative medicine products (Stemchymal®), and a global biorepository of over 600,000 human biospecimens. It serves pharmaceutical, biotechnology, academic, and government research customers across Japan, the US, UK, and India.

Product overview

REPROCELL is a global clinical and preclinical research company offering an integrated portfolio of stem cell, drug discovery, and diagnostic services. The company operates across four main segments: (1) Cell Therapy Developer Services, anchored by StemRNA™ reprogramming technology, StemEdit CRISPR gene editing platform, and GMP Master Cell Bank manufacturing for iPSC and MSC products; (2) Stem Cell Research Products including StemRNA™ reprogramming kits, NutriStem® culture media, iMatrix-511 laminin substrates, Alvetex® 3D culture systems, and ABLE®/BioThrust™ bioreactor systems; (3) Regenerative Medicine Products including Stemchymal® (adipose-derived MSC therapy for spinocerebellar ataxia), iGRP neural progenitor cells, TIL therapy, and GPC1 CAR-T therapy; and (4) Drug Discovery and Clinical Services including Bioserve global biorepository (600,000+ biospecimens), human tissue assays, Pharmacology-AI precision medicine platform, genomic services (DNA/RNA extraction, NGS, ctDNA), and central laboratory services. REPROCELL serves pharmaceutical and biotechnology companies through facilities in Japan, USA (Maryland), UK (Scotland/England), and India.

Differentiator

Problem solved

Functional benefit

Brands

• Bioserve: Human biospecimens and genomic services including DNA extraction, genotyping, biomarker discovery, and next-generation sequencing
• Stemgent
• Alvetex
• Biopta

Products and services

• StemRNA™ Reprogramming Technology Proprietary RNA-based reprogramming technology for generating induced pluripotent stem cells (iPSCs) from various cell sources including fibroblasts, blood cells, and urine-derived epithelial cells, without genomic integration. Offered as research-grade custom services for academic and commercial customers.
• StemEdit Gene Editing Platform AI-designed CRISPR gene editing platform providing custom genotypes for research and clinical iPSC projects, including knock-outs, knock-ins, and hypoimmune cell line generation using OpenCRISPR-1, the first fully AI-designed CRISPR-Cas editor.
• GMP Master Cell Bank Manufacturing FDA-compliant GMP manufacturing service for clinical-grade iPSC and MSC Master Cell Banks at the Beltsville, Maryland facility, with European alignment through Histocell partnership. Supported by active FDA Drug Master File.
• Stemchymal® Regenerative Medicine Product Adipose-derived mesenchymal stem cell product targeting spinocerebellar ataxia (SCA3 and SCA6), manufactured by Taiwan-based Steminent Biotherapeutics Inc., with Orphan Regenerative Medicine Product designation in Japan.
• iGRP (iPSC-derived Neural Glial Progenitor Cells) iPSC-derived neural glial progenitor cells targeting central nervous system disorders such as ALS and TM.
• TIL Therapy Tumor-infiltrating lymphocyte (TIL) therapy for cell-based immunotherapy targeting cancer.
• GPC1 CAR-T Therapy Glypican-1 CAR-T therapy as a cell-based immunotherapy for cancer.
• Alvetex® 3D Cell Culture Platform 3D cell culture and tissue bioengineering systems enabling scaffold-free and engineered tissue models for drug discovery and research.
• ABLE® Bioreactor Systems Single-use bioreactor systems for scalable iPSC culture and spheroid production in disease modeling and cell therapy development.
• BioThrust™ Bioreactor Systems Bioreactor systems for enhanced development of disease models and cell therapy applications.
• StemRNA™ 3rd Gen Reprogramming Kit RNA-based reprogramming kit for efficient generation of iPSCs from various starting cell types.
• NutriStem® hPSC XF Medium Defined, xeno-free, serum-free culture medium made to GMP specifications for propagation and expansion of human ESCs and iPSCs in feeder-free culture.
• iMatrix-511 Recombinant Laminin-511 E8 fragments providing a chemically-defined, xeno-free human laminin substrate for PSC growth and reprogramming.
• StemFactor Growth Factors and Cytokines Growth factors and cytokines for stem cell culture and differentiation applications.
• iPSC-derived Exosomes Purified exosomes derived from iPSCs for regenerative medicine and aesthetic applications.
• Bioserve Global Biorepository Global biorepository providing access to over 600,000 human DNA, serum, and tissue samples linked to detailed clinical and demographic data from 120,000+ consented and anonymized patients on four continents.
• Genomic Services Preclinical genomic services including DNA and RNA extraction, biomarker discovery and validation, real-time PCR, next-generation sequencing, and oligonucleotide synthesis.
• Pharmacology-AI Platform Precision medicine platform developed in collaboration with IBM and STFC that uses machine learning to rapidly identify features driving variation in patient outcomes, enabling patient stratification strategies for IBD and other therapeutic areas.
• Human Tissue Assays GLP contract research services using human fresh tissues and bioengineered 3D tissue models (IBD, skin, IPF, cardiovascular, respiratory) to characterize drug safety, efficacy, and absorption.
• REPROSKIN™ Bioengineered Skin Model Bioengineered human skin model for dermatological drug discovery and testing applications.
• Central Laboratory Services Integrated central laboratory services supporting clinical trial sample processing across USA, UK, India, and Japan with GLP/GCLP and ISO-compliant systems operational 24/7.
• ctDNA Detection Service Circulating tumor DNA extraction and analysis service from human plasma, including validated oncology panels for breast, lung, colon, pancreatic, and colorectal cancers.

Quantifiable outcome

• Access to 600,000+ biospecimens from 120,000+ consented donors
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• HistocellcoreStrategic or Co-development PartnerPartnership for European GMP manufacturing under EMA oversight. Histocell, based in Spain, provides manufacturing capabilities that complement REPROCELL's global GMP network, enabling European market access and regulatory compliance with European Medicines Agency standards.
• Steminent Biotherapeutics Inc.coreStrategic or Co-development PartnerTaiwan-based company that manufactures Stemchymal®, an allogeneic stem cell therapy product that REPROCELL commercializes in Japan. This partnership provides access to a validated stem cell therapy product for the Japanese market.
• IBMcoreTechnology or IntegrationCollaboration with IBM to develop the Pharmacology-AI platform for precision medicine services. IBM provides technical expertise and infrastructure for machine learning and AI capabilities in drug discovery and pharmacological analysis.
• STFC (Science and Technology Facilities Council)coreTechnology or IntegrationCollaboration with STFC to develop the Pharmacology-AI platform for precision medicine services. STFC provides scientific computing capabilities and research infrastructure supporting the development of AI-driven pharmacology solutions.
• Bioserve IndiacoreChannel Partner/ Reseller/ DistributorRegional distribution partnership for India market. Bioserve India serves as the exclusive or primary distributor for REPROCELL products and services in India, providing local sales, marketing, and customer support capabilities.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Pluristem Therapeutics: Develops placenta-derived allogeneic cell therapy products. Competes with ReproCELL's Stemchymal® and other MSC-based regenerative medicine products in similar orphan and rare disease indications.
• CellGenix (Sartorius): Supplier of GMP-grade raw materials for cell therapy manufacturing including growth factors and cytokines. Competes with ReproCELL's StemFactor reagents and CDMO-grade media supply.
• FUJIFILM Cellular Dynamics International: A direct iPSC peer — manufactures iPSC-derived cells and provides iPSC reprogramming and differentiation services for research and clinical use. Competes head-to-head with ReproCELL's StemRNA™ and iPSC lines across pharma, biotech, and academic customers globally.
• STEMCELL Technologies: A direct peer in stem cell research reagents, culture media, and cell isolation products. Competes with ReproCELL's NutriStem®, iMatrix-511, and other reagent products across academic and commercial stem cell researchers.

Emerging players

• Cytovia Therapeutics: Cell therapy developer focused on NK and CAR-NK cell therapies, including iPSC-derived approaches. Overlaps with ReproCELL's gene editing and iPSC platform for off-the-shelf cell therapy applications.
• Century Therapeutics: Clinical-stage iPSC-derived cell therapy developer using gene editing to create allogeneic therapies. Partial overlap with ReproCELL's iPSC + gene editing platform and uses similar upstream iPSC and hypoimmune engineering technologies.

Broad incumbents

• Bio-Techne: Major life science reagents and tools provider including stem cell culture media, growth factors, and analytical tools. Competes broadly with ReproCELL's research reagent portfolio across academic and pharma customers.
• Lonza Group: A global CDMO incumbent with extensive cell and gene therapy manufacturing capacity. Competes with ReproCELL's GMP iPSC and MSC manufacturing services at much greater scale, including in Japan, US, and Europe.
• Catalent (Novo Holdings): Major cell therapy CDMO offering GMP manufacturing for autologous and allogeneic cell therapies. Competes with ReproCELL for clinical-stage cell therapy manufacturing contracts and provides greater scale and global reach.
• Charles River Laboratories: Established CRO/CDMO with cell therapy manufacturing and preclinical research services. Competes with ReproCELL's drug discovery and GMP services across pharma and biotech clients with broader capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/reprocells
• LinkedInlinkedin.com/company/reprocell

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReproCELL